Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression
Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression
复制标题
DOI：
10.4088/jcp.16cs10905
复制
发表时间：
2018-01-01
影响因子：
5.3
通讯作者：
Lisanby, Sarah H.
中科院分区：
文献类型：
--
作者：
McClintock, Shawn M.;Reti, Irving M.;Lisanby, Sarah H.
目的：为重复经颅磁刺激（rTMS）治疗重度抑郁症（MDD）的安全有效应用提供专家建议。参与者：参与者包括一组17名临床专家和研究人员，他们在rTMS的临床应用方面具有专业知识，代表国家抑郁症中心网络（NNDC）rTMS工作组和美国精神病学协会研究理事会（阿帕CoR）新生物标志物和治疗工作组。证据：共识声明基于对1990年至2016年检索的2个数据库（OvidSP MEDLINE和PsycINFO）中的大量文献的综述。检索词包括重度抑郁症和经颅磁刺激的变体。结果仅限于以英语撰写的文章，重点是成年人。在检索到的约1，500项研究中，共有118篇出版物被纳入共识声明，并补充了专家意见，以就临床实践环境中rTMS治疗MDD的关键问题达成共识建议。共识过程：在研究证据不明确或不清楚的情况下，本文作者就如何实施rTMS达成了一致意见，并在文章中表示为“专家意见”。结论：多项随机对照试验和已发表的文献支持rTMS抗抑郁治疗的安全性和有效性。这些共识建议由NNDC rTMS工作组和阿帕CoR新型生物标志物和治疗工作组制定，为rTMS治疗MDD的安全有效临床应用提供了全面的信息。
Objective: To provide expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD).Participants: Participants included a group of 17 expert clinicians and researchers with expertise in the clinical application of rTMS, representing both the National Network of Depression Centers (NNDC) rTMS Task Group and the American Psychiatric Association Council on Research (APA CoR) Task Force on Novel Biomarkers and Treatments.Evidence: The consensus statement is based on a review of extensive literature from 2 databases (OvidSP MEDLINE and PsycINFO) searched from 1990 through 2016. The search terms included variants of major depressive disorder and transcranial magnetic stimulation. The results were limited to articles written in English that focused on adult populations. Of the approximately 1,500 retrieved studies, a total of 118 publications were included in the consensus statement and were supplemented with expert opinion to achieve consensus recommendations on key issues surrounding the administration of rTMS for MDD in clinical practice settings.Consensus Process: In cases in which the research evidence was equivocal or unclear, a consensus decision on how rTMS should be administered was reached by the authors of this article and is denoted in the article as "expert opinion."Conclusions: Multiple randomized controlled trials and published literature have supported the safety and efficacy of rTMS antidepressant therapy. These consensus recommendations, developed by the NNDC rTMS Task Group and APA CoR Task Force on Novel Biomarkers and Treatments, provide comprehensive information for the safe and effective clinical application of rTMS in the treatment of MDD.